Eagle Pharmaceuticals (EGRX) Reports Tough 3Q Results; Piper Jaffray Cuts Price target to $97

Go back to Eagle Pharmaceuticals (EGRX) Reports Tough 3Q Results; Piper Jaffray Cuts Price target to $97

Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 9c

November 11, 2015 7:04 AM EST

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of ($0.65), $0.09 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $5.07 million.

"Eagle has accomplished a great deal already this year, and we remain focused on achieving our goals in the particularly exciting and important final weeks ahead, said Scott Tarriff, President and Chief... More

Trading Radar for 11/11: Macy's (M), NetEase (NTES), Digital Ally (DGLY), Elbit Systems (ESLT) Report

November 10, 2015 3:20 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

ADT Corp. (NYSE: ADT) - consensus EPS $0.48
American DG Energy (NYSE: ADGE) - no Street consensus
Aqua Metals, Inc. (Nasdaq: AQMS) - consensus loss $0.08
Avolon Holdings Limited (Nasdaq: AVOL) - consensus EPS $0.78
CAE, Inc. (NYSE: CAE) - consensus EPS $0.18
CGI Group (NYSE: GIB) -... More